MARIETTA, Ga., Feb. 12, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants ...
GATWICK, England--(BUSINESS WIRE)--Systagenix (Gatwick, U.K.), announced today that it will launch EPIFIX ® in the United States in March as part of a global distribution agreement reached with MiMedx ...
MARIETTA, Georgia, Oct. 6, 2016 /PRNewswire/ -- MiMedx Group, Inc. MDXG, the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market ...
Wound healing in patients with diabetic ulcers is better with weekly applications of a dehydrated human amnion/chorion membrane allograft (EpiFix, MiMedx Group, Mariette, Georgia) compared with either ...
KENNESAW, Ga., Aug. 7, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed ...
MARIETTA, Ga., Oct. 18, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human ...
MARIETTA, Ga., Aug. 24, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that a new study regarding ...
MIMEDX aligns with a leading distributor of wound care products in Japan to capitalize on first-mover advantage for EPIFIX “We are delighted to join forces with the Gunze Medical team to bring EPIFIX ...
EPIFIX is a dehydrated human amnion/chorion membrane allograft used in wound healing. Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results